- Home
- SRTS vs MIST Comparison
SRTS vs MIST Comparison
Compare SRTS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- MIST
- Stock Information
- Founded
- SRTS 2010
- MIST 2003
- Country
- SRTS United States
- MIST Canada
- Employees
- SRTS N/A
- MIST N/A
- Industry
- SRTS Medical/Dental Instruments
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- MIST Health Care
- Exchange
- SRTS Nasdaq
- MIST Nasdaq
- Market Cap
- SRTS 88.7M
- MIST 98.1M
- IPO Year
- SRTS 2016
- MIST N/A
- Fundamental
- Price
- SRTS $4.77
- MIST $0.88
- Analyst Decision
- SRTS Strong Buy
- MIST Strong Buy
- Analyst Count
- SRTS 3
- MIST 2
- Target Price
- SRTS $13.00
- MIST $17.00
- AVG Volume (30 Days)
- SRTS 122.0K
- MIST 4.5M
- Earning Date
- SRTS 05-08-2025
- MIST 03-13-2025
- Dividend Yield
- SRTS N/A
- MIST N/A
- EPS Growth
- SRTS 1266.06
- MIST N/A
- EPS
- SRTS 0.41
- MIST N/A
- Revenue
- SRTS $41,807,000.00
- MIST N/A
- Revenue This Year
- SRTS $9.09
- MIST N/A
- Revenue Next Year
- SRTS $22.30
- MIST $1,105.43
- P/E Ratio
- SRTS $11.71
- MIST N/A
- Revenue Growth
- SRTS 71.31
- MIST N/A
- 52 Week Low
- SRTS $3.09
- MIST $0.75
- 52 Week High
- SRTS $9.33
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- SRTS 44.90
- MIST 30.59
- Support Level
- SRTS $4.46
- MIST $1.86
- Resistance Level
- SRTS $4.93
- MIST $2.36
- Average True Range (ATR)
- SRTS 0.20
- MIST 0.23
- MACD
- SRTS 0.09
- MIST -0.06
- Stochastic Oscillator
- SRTS 69.35
- MIST 7.43
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).